Reviewing Qiagen (NYSE:QGEN) & Dermata Therapeutics (NASDAQ:DRMA)

Qiagen (NYSE:QGEN) and Dermata Therapeutics (NASDAQ:DRMA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Qiagen and Dermata Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Qiagen	20.33%	14.56%	8.62%
Dermata Therapeutics	N/A	-191.95%	-140.15%

Valuation and Earnings

This table compares Qiagen and Dermata Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09 billion	4.90	$424.88 million	$2.02	24.03
Dermata Therapeutics	N/A	N/A	-$12.29 million	($7.81)	-0.15

Qiagen has higher revenue and earnings than Dermata Therapeutics. Dermata Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

70.0% of Qiagen shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 18.5% of Dermata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for Qiagen and Dermata Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0	8	4	0	2.33
Dermata Therapeutics	1	0	1	0	2.00

Qiagen currently has a consensus price target of $55.20, indicating a potential upside of 13.73%. Dermata Therapeutics has a consensus price target of $10.00, indicating a potential upside of 726.45%. Given Dermata Therapeutics’ higher possible upside, analysts plainly believe Dermata Therapeutics is more favorable than Qiagen.

Risk and Volatility

Qiagen has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Summary

Qiagen beats Dermata Therapeutics on 11 of the 13 factors compared between the two stocks.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

About Dermata Therapeutics

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.